Thrombocytopenia
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
| Thrombocytopenia Classification and external resources | |
| ICD-10 | D69.6, P61.0 |
|---|---|
| ICD-9 | 287.3, 287.4, 287.5 |
| OMIM | 188000 313900 |
| DiseasesDB | 27522 |
| MedlinePlus | 000586 |
| MeSH | D013921 |
|
WikiDoc Resources for Thrombocytopenia | |
|
Articles | |
|---|---|
|
Most recent articles on Thrombocytopenia Most cited articles on Thrombocytopenia | |
|
Media | |
|
Powerpoint slides on Thrombocytopenia | |
|
Evidence Based Medicine | |
|
Clinical Trials | |
|
Ongoing Trials on Thrombocytopenia at Clinical Trials.gov Trial results on Thrombocytopenia Clinical Trials on Thrombocytopenia at Google
| |
|
Guidelines / Policies / Govt | |
|
US National Guidelines Clearinghouse on Thrombocytopenia NICE Guidance on Thrombocytopenia
| |
|
Books | |
|
News | |
|
Commentary | |
|
Definitions | |
|
Patient Resources / Community | |
|
Patient resources on Thrombocytopenia Discussion groups on Thrombocytopenia Patient Handouts on Thrombocytopenia Directions to Hospitals Treating Thrombocytopenia Risk calculators and risk factors for Thrombocytopenia
| |
|
Healthcare Provider Resources | |
|
Causes & Risk Factors for Thrombocytopenia | |
|
Continuing Medical Education (CME) | |
|
International | |
|
| |
|
Businness | |
|
Experimental / Informatics | |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Phone:617-525-6884
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Thrombocytopenia (or -paenia, or thrombopenia in short) is the presence of relatively few platelets in blood.
Generally speaking a normal platelet count ranges from 150,000 and 450,000 per mm3. These limits, however, are determined by the 2.5th lower and upper percentile, and a deviation does not necessarily imply any form of disease. The number of platelets in a blood sample also decreases rather quickly with time and a low platelet count may be caused by a delay between sampling and analysis.
Signs and symptoms
Often, low platelet levels do not lead to clinical problems; rather, they are picked up on a routine full blood count (or CBC, complete blood count ). Occasionally, there may be bruising, particularly purpura in the forearms, nosebleeds and/or bleeding gums.
It is vital that a full medical history is elicited, to ensure the low platelet count is not due to a secondary process. It is also important to ensure that the other blood cell types red blood cells, and white blood cells, are not also suppressed.
Diagnosis
Laboratory tests might include: full blood count, liver enzymes, renal function, vitamin B12 levels, folic acid levels, erythrocyte sedimentation rate, and peripheral blood smear.
If the cause for the low platelet count remains unclear, bone marrow biopsy is often undertaken, to differentiate whether the low platelet count is due to decreased production or peripheral destruction.
Causes
Decreased platelet counts can be due to a number of disease processes:
Decreased production
- vitamin B12 or folic acid deficiency
- leukemia or myelodysplastic syndrome
- Decreased production of thrombopoietin by the liver in liver failure.
- Sepsis, systemic viral or bacterial infection
- Dengue fever can cause thrombocytopenia by direct infection of bone marrow megakaryocytes as well as immunological shortened platelet survival
- Hereditary syndromes
- Congenital Amegakaryocytic Thrombocytopenia (CAMT)
- Thrombocytopenia absent radius syndrome
- Fanconi anemia
- Bernard-Soulier syndrome, associated with large platelets
- May-Hegglin anomaly, the combination of thrombocytopenia, pale-blue leuckocyte inclusions, and giant platelets
- Grey platelet syndrome
- Alport syndrome
Increased destruction
- idiopathic thrombocytopenic purpura (ITP)
- thrombotic thrombocytopenic purpura (TTP)
- hemolytic-uremic syndrome (HUS)
- disseminated intravascular coagulation (DIC)
- paroxysmal nocturnal hemoglobinuria (PNH)
- antiphospholipid syndrome
- systemic lupus erythematosus (SLE)
- post transfusion purpura
- neonatal alloimmune thrombocytopenia (NAITP)
- Splenic sequestration of platelets due to hypersplenism
- Dengue fever has been shown to cause shortened platelet survival and immunological platelet destruction
- HIV http://linkinghub.elsevier.com/retrieve/pii/S0268960X01901882
Medication-induced
The most comprehensive list of thrombocytopenia-inducing medications is maintained by Dr. James George at Ohio State University at this website, though last updated in 2004. A small subset of drug-induced thrombocytopenia culprits:
- Direct myelosuppression
- Valproic acid
- Methotrexate
- Carboplatin
- Interferon
- Other chemotherapy drugs
- Immunological platelet destruction
- Drug binds Fab portion of an antibody. The classic example of this mechanism is the quinidine group of drugs. The Fc portion of the antibody molecule is not involved in the binding process.
- Drug binds to Fc, and drug-antibody complex binds and activates platelets. Heparin induced thrombocytopenia (HIT) is the classic example of this phenomenon. In HIT, the heparin-antibody-platelet factor 4 (PF4) complex binds to Fc receptors on the surface of the platelet. Since Fc portion of the antibody is bound to the platelets, they are not available to the Fc receptors of the reticulo-endothelial cells, so therefore this system cannot destroy platelets as usual. This may explain why severe thrombocytopenia is not a common feature of HIT.
- Heparin-induced thrombocytopenia (HIT or white clot syndrome): this is a rare but serious condition that may occur in a hospitalized population. The most common clinical setting for HIT is in postoperative coronary artery bypass graft recipients, who may receive large quantities of heparin during surgery. HIT typically occurs about a week after exposure to heparin. The heparin-PF4 antibody complex will activate the platelets, and this can often lead to thrombosis. The term HITT, where the last T stands for thrombosis, denotes the concept that heparin-induced thrombocytopenia often is associated with thrombosis.
Treatment
Treatment is guided by etiology and disease severity. The main concept in treating thrombocytopenia is to eliminate the underlying problem, whether that means discontinuing suspected drugs that cause thrombocytopenia, or treating underlying sepsis. Diagnosis and treatment of serious thrombocytopenia is usually directed by a hematologist.
Specific treatment plans often depend on the underlying etiology of the thrombocytopenia.
Thrombotic thrombocytopenic purpura (TTP)
Treatment of thrombotic thrombocytopenic purpura is a medical emergency, since the hemolytic anemia and platelet activation can lead to renal failure and changes in the level of consciousness. Treatment of TTP was revolutionized in the 1980s with the application of plasmapheresis. According to the Furlan-Tsai hypothesis [1] [1] , this treatment theoretically works by removing antibodies directed against the von Willebrand factor cleaving protease, ADAMTS-13. The plasmapheresis procedure also adds active ADAMTS-13 protease proteins to the patient, restoring a more physiological state of von Willebrand factor multimers. Patients with persistent antibodies against ADAMTS-13 do not always manifest TTP, and these antibodies alone are not sufficient to explain the how plasmapheresis treats TTP.
ITP
In many cases, ITP is self-limited, and does not require treatment. Platelet counts less than ten thousand per mm3 usually require treatment(less than fifty thousand requires treatment, less than ten thousand is a potentially dangerous situation) and patients with significant bleeding and thrombocytopenia due to ITP are also usually treated. The threshold for treating ITP has decreased since the 1990s, and hematologists recognize that patients rarely bleed with platelet counts greater than ten thousand, though there are documented exceptions to this observation. Treatments for ITP include:
Thrombopoetin analogues have been tested extensively for the treatment of ITP. These agents had previously shown promise but had been found to stimulate antibodies against endogenous thrombopoeitin or lead to thrombosis.
A medication known as AMG 531 was found to be safe and effective for the treatment of ITP in refractory patients. [1] AMG 531 is a peptide that bears no sequence homology with endogenous human thrombopoeitin, so it is not as likely to lead to neutralizing antibodies as previous peptide thrombopoeitin analogues. [1]
Heparin-induced thrombocytopenia and thrombosis (HITT)
Discontinuation of heparin is critical in a case of HITT. Beyond that, however, care must be taken to avoid a thrombosis, and patients started directly on warfarin after a diagnosis of HITT are at excess risk of venous limb gangrene. For this reason, patients are usually treated with a type of blood thinner called a direct thrombin inhibitor such as the FDA-approved lepirudin or argatroban. Other blood thinners sometimes used in this setting that are not FDA-approved for treatment of HITT include bivalirudin and fondaparinux. Platelet transfusions are not a routine component of the treatment of HITT, since thrombosis, not bleeding, is the usual associated problem in this illness.
Congenital amegakaryocytic thrombocytopenia (CAMT)
Bone Marrow/Stem Cell Transplant is the only thing that ultimately cures this genetic disease. Frequent platelet transfusions are required to keep the patient from bleeding to death until transplant is done.
References
External links
- 11-133b. at Merck Manual of Diagnosis and Therapy Professional Edition
WikiDoc Research Resources for Thrombocytopenia | |
|---|---|
| Articles on Thrombocytopenia | Most recent articles on Thrombocytopenia • Most cited articles on Thrombocytopenia • Review articles on Thrombocytopenia • Articles on Thrombocytopenia in N Eng J Med, Lancet, BMJ |
| Media (Slides, Video, Images, MP3) on Thrombocytopenia | Powerpoint slides on Thrombocytopenia • Images of Thrombocytopenia • Photos of Thrombocytopenia • Podcasts & MP3s on Thrombocytopenia • Videos on Thrombocytopenia |
| Evidence Based Medicine Regarding Thrombocytopenia | Cochrane Collaboration on Thrombocytopenia • Bandolier on Thrombocytopenia • TRIP on Thrombocytopenia |
| Cost Effectiveness of Thrombocytopenia | Cost Effectiveness of Thrombocytopenia |
| Clinical Trials Involving Thrombocytopenia | Ongoing Trials on Thrombocytopenia at Clinical Trials.gov • Trial results on Thrombocytopenia • Clinical Trials on Thrombocytopenia at Google |
| Guidelines / Policies / Government Resources (FDA/CDC) Regarding Thrombocytopenia | US National Guidelines Clearinghouse on Thrombocytopenia • NICE Guidance on Thrombocytopenia • NHS PRODIGY Guidance • FDA on Thrombocytopenia • CDC on Thrombocytopenia |
| Textbook Information on Thrombocytopenia | Books and Textbook Information on Thrombocytopenia |
| Pharmacology Resources on Thrombocytopenia | Dosing of Thrombocytopenia • Drug interactions with Thrombocytopenia • Side effects of Thrombocytopenia • Allergic reactions to Thrombocytopenia • Overdose information on Thrombocytopenia • Carcinogenicity information on Thrombocytopenia • Thrombocytopenia in pregnancy • Pharmacokinetics of Thrombocytopenia • |
| Genetics, Pharmacogenomics, and Proteinomics of Thrombocytopenia | Genetics of Thrombocytopenia • Pharmacogenomics of Thrombocytopenia • Proteomics of Thrombocytopenia |
| Newstories on Thrombocytopenia | Thrombocytopenia in the news • Be alerted to news on Thrombocytopenia • News trends on Thrombocytopenia |
| Commentary on Thrombocytopenia | Blogs on Thrombocytopenia |
| Patient Resources on Thrombocytopenia | Patient resources on Thrombocytopenia • Discussion groups on Thrombocytopenia • Patient Handouts on Thrombocytopenia • Directions to Hospitals Treating Thrombocytopenia • Risk calculators and risk factors for Thrombocytopenia |
| Healthcare Provider Resources on Thrombocytopenia | Symptoms of Thrombocytopenia • Causes & Risk Factors for Thrombocytopenia • Diagnostic studies for Thrombocytopenia • Treatment of Thrombocytopenia |
| Continuing Medical Education (CME) Programs on Thrombocytopenia | CME Programs on Thrombocytopenia |
| International Resources on Thrombocytopenia | Thrombocytopenia en Espanol • Thrombocytopenia en Francais |
| Business Resources on Thrombocytopenia | Thrombocytopenia in the Marketplace • Patents on Thrombocytopenia |
| Informatics Resources on Thrombocytopenia | List of terms related to Thrombocytopenia |
hr:Trombocitopenija id:Trombositopenia it:Piastrinopenia mk:Тромбоцитопенија nl:Trombocytopeniesv:Trombocytopeni
| ||||
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
